Medications
Peter Attia's prescription lipid therapy as stated in October 2023: Repatha twice monthly and Nexlizet, used to target apoB of 30–40 mg/dL. He separately reported stopping metformin in 2019 and stopping rapamycin 'for now' by October 2025 after mouth sores. No current dose is inferred for either stopped drug.
Interventions
Tap an intervention for its use, evidence and other protocols.
Medications
- 01Evolocumab, PCSK9 inhibitorViewRepathaTwice monthly injection
Genetic cardiovascular risk; targeting apoB of 30–40 mg/dL from a baseline of about 90–100
- 02Bempedoic acid + ezetimibeViewNexlizetDaily
Same apoB target of 30–40 mg/dL; he reported no side effects for himself
- 03
Previously taken experimentally for longevity; stopped after mouth sores
- 04
Previously taken for longevity, not diabetes
Sources
- 01The Drive #276: Peter answers questions on longevity, supplements, protein, fasting, apoB, statins, and moreRepatha (evolocumab, PCSK9 inhibitor)
- 02Dr. Peter Attia says enjoying a longer, healthier life requires serious trainingRapamycin
- 03Metformin and exercise — déjà vu all over again?Metformin